Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M205Revenue $M0.0Net Margin (%)-406,700.0Z-Score33.6
Enterprise Value $M158EPS $-1.4Operating Margin %-406,700.0F-Score3
P/E(ttm))0Cash Flow Per Share $-1.0Pre-tax Margin (%)-406,700.0Higher ROA y-yY
Price/Book4.810-y EBITDA Growth Rate %-14.7Quick Ratio16.0Cash flow > EarningsY
Price/Sales21,9485-y EBITDA Growth Rate %-13.1Current Ratio16.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-51.0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-54.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M24.3ROI % (ttm)-56.0Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RPRXJohn Paulson 2014-12-31 Sold Out -0.04%$6.02 - $10.69
($8.49)
$ 8.43-1%Sold Out0
RPRXJohn Paulson 2014-09-30 Buy 0.04%$8.77 - $22.16
($14.84)
$ 8.43-76%New holding1,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RPRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PODOLSKI JOSEPHPresident and CEO 2014-11-12Buy4,700$9.42-10.51view
Anderson KatherineCFO 2014-11-12Buy3,500$9.41-10.41view
Masterson Nola EDirector 2014-09-15Buy200$14.34-41.21view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-39.13view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-39.4view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-43.69view
Anderson KatherineCFO 2013-10-25Buy1,000$17.9-52.91view
PODOLSKI JOSEPHPresident and CEO 2013-10-25Buy3,000$18.03-53.24view
Anderson KatherineCFO 2013-10-10Buy1,000$23.77-64.54view
Anderson KatherineCFO 2013-02-01Buy1,000$11.89-29.1view

Press Releases about RPRX :

    Quarterly/Annual Reports about RPRX:

    News about RPRX:

    Articles On GuruFocus.com
    comment on RPRX Mar 06 2013 
    Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
    promotes testosteron Jun 22 2011 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
    Repros Therapeutics Inc. Reports Second Quarter 2009 Financial Results and Provides Update Aug 17 2009 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 


    More From Other Websites
    Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application Apr 15 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Apr 15 2015
    Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application Apr 15 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events Apr 13 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Apr 08 2015
    Repros Gets EU Update on Secondary Hypogonadism Drug - Analyst Blog Apr 07 2015
    Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization... Apr 06 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Apr 06 2015
    Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization... Apr 06 2015
    Repros' Secondary Hypogonadism Drug Under FDA Review - Analyst Blog Apr 02 2015
    Lumber Liquidators, CarMax are big market movers Apr 02 2015
    Lumber Liquidators, CarMax are big market movers Apr 02 2015
    Repros shares rally on testicle-stimulation drug application Apr 01 2015
    Repros Announces Acceptance for Filing of NDA Apr 01 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Apr 01 2015
    Repros Announces Acceptance for Filing of NDA Apr 01 2015
    REPROS THERAPEUTICS INC. Financials Mar 20 2015
    Repros (RPRX) Incurs Narrower-than-Expected Loss in Q4 - Tale of the Tape Mar 16 2015
    Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2014 Financial Results Mar 16 2015
    Repros Therapeutics reports 4Q loss Mar 16 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK